Sustained complete remission of human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver during long-term trastuzumab (Herceptin) maintenance therapy in a woman: a case report

Case Report ◽

Growth Factor ◽

Complete Remission ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

International Cancer Conference Journal ◽

10.1007/s13691-016-0253-y ◽

2016 ◽

Vol 5 (4) ◽

pp. 178-182 ◽

Cited By ~ 1

Author(s):

Toshiaki Saeki ◽

Kazuhiro Araki ◽

Ken Shimada ◽

Takashi Shigekawa ◽

Hirofumi Nakayama ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Combination Chemotherapy ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Effect of Hormone Therapy on Long-term Outcomes of Patients with Human Epidermal Growth Factor Receptor 2-and Hormone Receptor-Positive Metastatic Breast Cancer: Real World Experience in China

Asian Pacific Journal of Cancer Prevention ◽

10.7314/apjcp.2015.16.3.903 ◽

2015 ◽

Vol 16 (3) ◽

pp. 903-907 ◽

Cited By ~ 2

Author(s):

Feng Du ◽

Peng Yuan ◽

Jia-Yu Wang ◽

Fei Ma ◽

Ying Fan ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Long Term Outcomes ◽

Hormone Receptor Positive ◽

Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)

European Journal of Cancer ◽

10.1016/j.ejca.2021.05.025 ◽

2021 ◽

Vol 153 ◽

pp. 223-233

Author(s):

Volkmar Mueller ◽

Andrew Wardley ◽

Elisavet Paplomata ◽

Erika Hamilton ◽

Amelia Zelnak ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India

ecancermedicalscience ◽

10.3332/ecancer.2021.1207 ◽

2021 ◽

Vol 15 ◽

Author(s):

Anjana Joel ◽

Josh Thomas Georgy ◽

Divya Bala Thumaty ◽

Ajoy Oommen John ◽

Raju Titus Chacko ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Neoadjuvant Chemotherapy ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Patterns Of Use ◽

Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2–negative Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.09.007 ◽

2020 ◽

Vol 20 (2) ◽

pp. 160-167

Author(s):

John Smith ◽

Amy Irwin ◽

Lori Jensen ◽

Karen Tedesco ◽

Soamnauth Misir ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Eribulin Mesylate ◽

Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis

Annals of Oncology ◽

10.1093/annonc/mdw337.21 ◽

2016 ◽

Vol 27 ◽

pp. iv65

Author(s):

L. Pizzuti ◽

I. Sperduti ◽

A. Michelotti ◽

C. Omarini ◽

T. Gamucci ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Chromosome 17 Polysomy without Human Epidermal Growth Factor Receptor 2 Amplification Does Not Predict Response to Lapatinib Plus Paclitaxel Compared with Paclitaxel in Metastatic Breast Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-09-1643 ◽

2010 ◽

Vol 16 (4) ◽

pp. 1281-1288 ◽

Cited By ~ 27

Author(s):

L. Downey ◽

R. B. Livingston ◽

M. Koehler ◽

M. Arbushites ◽

L. Williams ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Chromosome 17 ◽

Human Epidermal Growth Factor ◽

Efficacy and safety of bevacizumab in the treatment of human epidermal growth factor receptor type 2 negative metastatic breast cancer: About a large series in moroccan population

Indian Journal of Cancer ◽

10.4103/0019-509x.146779 ◽

2014 ◽

Vol 51 (3) ◽

pp. 272 ◽

Cited By ~ 1

Author(s):

N Majid ◽

S Boutayeb ◽

H Errihani

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Phase II study of weekly administration of docetaxel (D) in combination with the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in metastatic breast cancer (MBC).

10.1158/0008-5472.sabcs-3124 ◽

2009 ◽

Author(s):

H Kaur ◽

P Silverman ◽

D Singh ◽

P Fu ◽

R Farag ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Egfr Inhibitor ◽

Weekly Administration ◽

Abstract P1-13-06: Impact of visceral metastases on treatment patterns for hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC)

10.1158/1538-7445.sabcs14-p1-13-06 ◽

2015 ◽

Author(s):

James Signorovitch ◽

Jenny Wang ◽

Ruo-Ding Tan ◽

Darren Thomason ◽

Andrew Kageleiry ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Treatment Patterns ◽

Hormone Receptor Positive ◽

Visceral Metastases ◽